JP2017534572A5 - - Google Patents

Download PDF

Info

Publication number
JP2017534572A5
JP2017534572A5 JP2017512313A JP2017512313A JP2017534572A5 JP 2017534572 A5 JP2017534572 A5 JP 2017534572A5 JP 2017512313 A JP2017512313 A JP 2017512313A JP 2017512313 A JP2017512313 A JP 2017512313A JP 2017534572 A5 JP2017534572 A5 JP 2017534572A5
Authority
JP
Japan
Prior art keywords
hydrogen
optionally substituted
group
independently
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017512313A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534572A (ja
JP6782227B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/048640 external-priority patent/WO2016037106A1/en
Publication of JP2017534572A publication Critical patent/JP2017534572A/ja
Publication of JP2017534572A5 publication Critical patent/JP2017534572A5/ja
Priority to JP2020097823A priority Critical patent/JP6918378B2/ja
Application granted granted Critical
Publication of JP6782227B2 publication Critical patent/JP6782227B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017512313A 2014-09-05 2015-09-04 CaMKII阻害剤及びその使用 Active JP6782227B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020097823A JP6918378B2 (ja) 2014-09-05 2020-06-04 CaMKII阻害剤及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046450P 2014-09-05 2014-09-05
US62/046,450 2014-09-05
PCT/US2015/048640 WO2016037106A1 (en) 2014-09-05 2015-09-04 CaMKII INHIBITORS AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020097823A Division JP6918378B2 (ja) 2014-09-05 2020-06-04 CaMKII阻害剤及びその使用

Publications (3)

Publication Number Publication Date
JP2017534572A JP2017534572A (ja) 2017-11-24
JP2017534572A5 true JP2017534572A5 (enExample) 2018-10-11
JP6782227B2 JP6782227B2 (ja) 2020-11-11

Family

ID=54150675

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017512313A Active JP6782227B2 (ja) 2014-09-05 2015-09-04 CaMKII阻害剤及びその使用
JP2020097823A Expired - Fee Related JP6918378B2 (ja) 2014-09-05 2020-06-04 CaMKII阻害剤及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020097823A Expired - Fee Related JP6918378B2 (ja) 2014-09-05 2020-06-04 CaMKII阻害剤及びその使用

Country Status (7)

Country Link
US (2) US10759792B2 (enExample)
EP (1) EP3189052B1 (enExample)
JP (2) JP6782227B2 (enExample)
CN (1) CN107074856A (enExample)
AU (2) AU2015311730A1 (enExample)
CA (1) CA2960101C (enExample)
WO (1) WO2016037106A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
EP3681489A4 (en) * 2017-09-10 2021-05-26 Carmel Haifa University Economic Corporation Ltd. METHOD OF TREATMENT OF DEPRESSION AND SEVERE DEPRESSION
CN108218862B (zh) * 2018-02-07 2020-06-23 贵州医科大学 α-卡波林类衍生物在制备抗心肌缺氧复氧损伤药物中的应用
JP7500426B2 (ja) 2018-02-21 2024-06-17 ブリストル-マイヤーズ スクイブ カンパニー Camk2dアンチセンスオリゴヌクレオチドおよびその使用
CN108904532B (zh) * 2018-08-20 2021-07-27 上海市第一人民医院 一种富勒烯C60纳米晶体联合CaMKII抑制剂的组合物的应用
JP7463369B2 (ja) * 2018-11-27 2024-04-08 エフ. ホフマン-ラ ロシュ アーゲー 細菌性感染症の処置および予防のためのアリール化合物
PE20240148A1 (es) * 2020-09-28 2024-02-06 Cardurion Pharmaceuticals Inc COMPUESTOS DE HETEROARILO FUSIONADO Y SU USO COMO INHIBIDORES DE CaMKII

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1913124A (en) * 1932-01-02 1933-06-06 American Sundries Co Inc Vaporizer
US2690441A (en) * 1953-06-11 1954-09-28 Searle & Co 3-carboline derivatives
GB1268773A (en) 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
BE758991A (fr) * 1969-11-18 1971-05-17 Reeves Bros Inc Procede de reticulation hydrodynamique d'une mousse de polyurethanne
PL80610B1 (enExample) * 1970-03-12 1975-08-30
GB8600651D0 (en) * 1986-01-11 1986-02-19 Beecham Group Plc Compounds
DE4435477A1 (de) 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
AU6257798A (en) 1997-01-31 1998-08-25 Board Of Trustees Of The Leland Stanford Junior University Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
BR0213043A (pt) 2001-10-01 2004-10-05 Univ Vanderbilt Métodos de tratar ou prevenir dusfunção contrátil miocárdica após infarto do miocárdio em um sujeito, de tratar ou prevenir cardiomiopatia dilatada em um sujeito e de incrementar contratilidade miocárdica em um sujeito, animal transgênico, e, método de identificar um composto que pode tratar doença estrutural do coração
WO2004058764A1 (en) 2002-12-27 2004-07-15 Bayer Healthcare Ag 4-phenyl-pyrimido [4,5-b] indole derivatives
WO2006007422A2 (en) 2004-06-16 2006-01-19 The Trustees Fo Columbia University In The City Of New York CaMKII/CALCIUM CHANNEL PHOSPHORYLATION-RELATED COMPOSITIONS AND METHODS
FR2876377B1 (fr) 2004-10-11 2007-03-16 Univ Claude Bernard Lyon Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
CN101052420A (zh) 2004-11-02 2007-10-10 大日本住友制药株式会社 用于治疗自体免疫疾病的并用药
BRPI0610828A2 (pt) 2005-05-16 2010-07-27 Irm Llc compostos e composições como inibidores de proteìna quinase
ES2380795T3 (es) 2005-05-20 2012-05-18 Vertex Pharmaceuticals, Inc. Pirrolopiridinas útiles como inhibidores de proteínas quinasas
JP2008542433A (ja) 2005-06-09 2008-11-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング CDK−1インヒビターとしてのα−カルボリン
JP2009500475A (ja) 2005-07-01 2009-01-08 ザ テキサス エイ アンド エム ユニヴァーシティ システム 酸化亜鉛ポリマーナノ複合材料及び酸化亜鉛ポリマーナノ複合材料の製造方法
EP1979353A2 (en) 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
CL2008001540A1 (es) 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
SI2247558T2 (sl) * 2008-02-14 2024-10-30 Eli Lilly And Company Nova kontrastna sredstva za zaznavanje nevroloških disfunkcij
WO2010011768A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
EP2323482A4 (en) 2008-08-06 2011-08-17 Merck & Co Inc SUBSTITUTED DIHYDROISOCHINOLINONE AND ISOCHINOLINDION DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
EP2161271A1 (en) 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
CA2742320A1 (en) 2008-10-31 2010-05-06 Medivation Technologies, Inc. Pyrido[4,3-b]indoles containing rigid moieties
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Eg5阻害剤
US8440656B2 (en) 2009-06-22 2013-05-14 University Of Iowa Research Foundation Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity
EP2582668B1 (en) 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
WO2013042035A1 (en) * 2011-09-19 2013-03-28 Vitas Pharma Research Private Limited Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections
EP2900666B1 (en) * 2012-09-28 2020-11-04 Cancer Research Technology Limited Azaquinazoline inhibitors of atypical protein kinase c
WO2014138212A1 (en) 2013-03-06 2014-09-12 Allosteros Therapeutics, Inc. CaMKII INHIBITORS AND USES THEREOF

Similar Documents

Publication Publication Date Title
JP2017534572A5 (enExample)
EP3490565B1 (en) Azetidine derivatives as chemokine receptor modulators and uses thereof
JP2016512198A5 (enExample)
CN110177788B (zh) 作为bcl-2选择性凋亡诱导剂的化合物
JP2018522866A5 (enExample)
JP6342805B2 (ja) 置換ピラゾロ[3,4−d]ピリミジンおよびその用途
AU2014239995B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
JP2019527682A5 (enExample)
JP2018522867A5 (enExample)
JP2011506588A5 (enExample)
JP2019510787A5 (enExample)
JP2017537940A5 (enExample)
KR20160062103A (ko) 브루톤 티로신 키나제의 억제제
JP2022506686A (ja) ピリダジノン化合物およびその使用
JP2015500236A (ja) 7−(6−(2−ヒドロキシプロパン−2−イル)ピリジン−3−イル)−1−((トランス)−4−メトキシシクロヘキシル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オンの薬剤組成物、その固体形態、およびその使用方法
JP2015508092A5 (enExample)
CN104520291A (zh) 用于调节egfr活性的化合物和组合物
JP2021508318A (ja) チューブリン阻害剤
JP2019521964A5 (enExample)
JP2025502748A (ja) Flt3の阻害剤としてのピラジン化合物
JP2022520907A (ja) Nurr1受容体調節因子
KR20140023332A (ko) 티에노〔2,3­d〕피리미딘 유도체 및 부정맥을 치료하기 위한 이의 용도
JP5881864B2 (ja) 炭素環ヌクレオシドならびにその医薬的使用および組成物
JPS63255266A (ja) 抗不整脈剤
DK2603486T3 (en) Panthenyldocosahexaenoate and its use in the treatment and prevention of cardiovascular diseases